United States - English - NLM (National Library of Medicine)

xceptor llc - methyl salicylate  10% - topical analgesic topical pain relief for minor aches and pains.

United States - English - NLM (National Library of Medicine)

sato pharmaceutical co., ltd. - methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz), levomenthol (unii: bz1r15mtk7) (levomenthol - unii:bz1r15mtk7), camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et) - methyl salicylate 10 g in 100 ml - purpose dl-camphor    external analgesic l-menthol        external analgesic methyl salicylate    external analgesic uses    temporary relieves minor aches and pains of muscles and joints due to ■ backache   ■ arthritis   ■ strains   ■ bruises   ■sprains

United States - English - NLM (National Library of Medicine)

greenstone pharmaceutical inc. - camphor (synthetic) (unii: 5tjd82a1et) (camphor (synthetic) - unii:5tjd82a1et), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a), methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - camphor (synthetic) 11 g in 100 g - topical analgesic topical analgesic topical analgesic for temporary relief of minor aches and pains of muscles and joints associated with: simple backache       arthritis      rheumatism      muscle strain      sprains      bruises for temporary relief of pain and itching associated with: insect bites      minor skin irritation stop use and ask a doctor if: skin redness or excessive irritation of the skin occurs condition worsens symptoms persists for more than 7 days or clears up and occurs again within a few days do not bandage tightly

United States - English - NLM (National Library of Medicine)

p.s.w. inc. - camphor              22%, menthol               16%, methyl salicylate  3% - topical analgesic for temporary relief of minor aches and pains of muscles and joints associated with over-exertion, simple backache, arthritis, strains and sprains.

United States - English - NLM (National Library of Medicine)

sinsin pharmaceutical co., ltd. - dl-camphor (1.21%), l-menthol (5.54%), methyl salicylate (6.11%) - topical analgesic for the temporarily relief of minor aches and pains of muscles and joints associated with: - arthritis  - simple backache  - strains - bruises  - sprains

United States - English - NLM (National Library of Medicine)

sinsin pharmaceutical co., ltd. - l-menthol, methyl salicylate, dl-camphor, chlorpheniramine maleate, thymol - topical analgesic for the temporarily relief of minor aches and pains of muscles and joints associated with: - arthritis - simple backache - strains - bruises - sprains

United States - English - NLM (National Library of Medicine)

medsource pharmaceuticals - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone tablets are indicated in the following conditions: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoids supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic cardit

United States - English - NLM (National Library of Medicine)

amneal pharmaceuticals llc - methylprednisolone (unii: x4w7zr7023) (methylprednisolone - unii:x4w7zr7023) - methylprednisolone tablets are indicated in the following conditions: 1.      endocrine disorders primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). congenital adrenal hyperplasia nonsuppurative thyroiditis hypercalcemia associated with cancer 2.      rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ankylosing spondylitis acute and subacute bursitis synovitis of osteoarthritis acute nonspecific tenosynovitis post-traumatic osteoarthritis psoriatic arthritis epicondylitis acute gouty arthritis 3.      collagen diseases during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus systemic dermatomyositis (polymyositis) acute rheumatic carditis 4.      dermatologic diseases bullous dermatitis herpetiformis severe erythema multiforme (stevens-johnson syndrome) severe seborrheic dermatitis exfoliative dermatitis mycosis fungoides pemphigus severe psoriasis 5.      allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis drug hypersensitivity reactions serum sickness contact dermatitis bronchial asthma atopic dermatitis 6.      ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers herpes zoster ophthalmicus anterior segment inflammation diffuse posterior uveitis and choroiditis sympathetic ophthalmia keratitis optic neuritis allergic conjunctivitis chorioretinitis iritis and iridocyclitis 7.      respiratory diseases symptomatic sarcoidosis berylliosis loeffler’s syndrome not manageable by other means fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy aspiration pneumonitis 8.      hematologic disorders idiopathic thrombocytopenic purpura in adults secondary thrombocytopenia in adults acquired (autoimmune) hemolytic anemia erythroblastopenia (rbc anemia) congenital (erythroid) hypoplastic anemia 9.      neoplastic diseases for palliative management of: leukemias and lymphomas in adults acute leukemia of childhood 10.  edematous states to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.  gastrointestinal diseases to tide the patient over a critical period of the disease in: ulcerative colitis regional enteritis 12.  nervous system acute exacerbations of multiple sclerosis 13.  miscellaneous tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. trichinosis with neurologic or myocardial involvement. systemic fungal infections and known hypersensitivity to components.

United States - English - NLM (National Library of Medicine)

alexso, inc - methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - methyl salicylate 10% …………………………..…………………….….…topical analgesic for the temporary relief of minor aches and pains of muscles and joints, such as simple backache, lumbago, arthritis, neuralgia, strains, bruises, and sprains.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - methyl salicylate (unii: lav5u5022y) (salicylic acid - unii:o414pz4lpz) - methyl salicylate 10% …………………………..…………………….….…topical analgesic for the temporary relief of minor aches and pains of muscles and joints, such as simple backache, lumbago, arthritis, neuralgia, strains, bruises, and sprains.